AffiliationDepartment of Endocrinology, Christie Hospital, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractAcromegaly, a condition due to growth hormone hypersecretion usually from a benign pituitary tumour, is associated with significant morbidity and mortality. Disease control leads to normalisation of life expectancy with a reduction in signs and symptoms. Treatment modalities include surgery, radiotherapy and medical management. Surgery is the primary treatment in most of the patients, with success rates of 61-91% reported for those with microadenomas who are operated on by a specialist pituitary surgeon; however, most patients have macroadenomas and, although benefiting from surgery, are not cured and require additional medical therapy. This review will focus on emerging concepts in the medical treatment of acromegaly.
CitationRecent developments in the therapy of acromegaly. 2006, 15 (3):251-6 Expert Opin Investig Drugs
JournalExpert Opinion on Investigational Drugs
- Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University.
- Authors: Fukuda I, Hizuka N, Murakami Y, Itoh E, Yasumoto K, Sata A, Takano K
- Issue date: 2001 Oct
- Therapy for the syndromes of GH excess.
- Authors: Arosio M, Cannavò S, Epaminonda P, Ronchi C, Chiodini I, Adda G
- Issue date: 2003
- Changing paradigms in the surgical and medical management of acromegaly.
- Authors: Stoller WA
- Issue date: 2006 Sep
- The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
- Authors: Bastemir M, Akin F, Yaylali GF
- Issue date: 2007
- A follow-up of 130 patients with acromegaly in a single centre.
- Authors: Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek-Tupikowska G, Bohdanowicz-Pawlak A, Daroszewski J, Szymczak J, Podgorski JK
- Issue date: 2006 Dec